Can zoledronic acid be beneficial for promoting tumor response in breast cancer patients treated with neoadjuvant chemotherapy?

Abstract

The antitumor effect of bisphosphonates (BPs) is under increasing scrutiny. Preclinical and clinical evidence has shown that BPs might sensitize breast tumors to chemotherapy. Here, we present a review of current preclinical and clinical evidence for antitumor effects of BPs, and evaluate how BPs might play a role in neoadjuvant treatment of women with breast cancer. © 2013 by the authors; licensee MDPI, Basel, Switzerland.